← Back to Search

Vitamin

Nicotinamide Riboside for Ovarian Cancer

Phase 2
Waitlist Available
Led By Alexandra Thomas, MD
Research Sponsored by Donna Hammond, PhD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether nicotinamide riboside (a form of vitamin B3) can prevent nerve pain in cancer patients receiving certain chemotherapy drugs. It works by increasing NAD+ levels to protect nerve cells. The study focuses on patients with specific types of cancer who are experiencing nerve pain from their treatment.

Eligible Conditions
  • Head and Neck Cancers
  • Breast cancer
  • Endometrial Cancer
  • Peripheral Neuropathy
  • Ovarian Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With No Worsening in the Grade of Peripheral Sensory Neuropathy as Scored by CTCAE
Secondary study objectives
Difference in Score Between Baseline and End of Treatment for the FACT&GOG-NTX Subscale .
Number of Dose Reduction Events
Percentage of Patients in Which Dose of Paclitaxel or Nab-Paclitaxel is Reduced Due to CIPN
+1 more
Other study objectives
Difference in Total Neuropathy Score Between Screening and End of Treatment

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NIAGEN®)Experimental Treatment1 Intervention
Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide riboside
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Donna Hammond, PhDLead Sponsor
1 Previous Clinical Trials
48 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,925 Previous Clinical Trials
41,017,996 Total Patients Enrolled
289 Trials studying Ovarian Cancer
76,483 Patients Enrolled for Ovarian Cancer
ChromaDex, Inc.Industry Sponsor
7 Previous Clinical Trials
393 Total Patients Enrolled
~1 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top